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See Article, pages 934–940The prevalence of non-alcoholic fatty liver disease (NAFLD) has
shown a dramatic increase over recent years and is now reaching
epidemic proportions. It is becoming increasingly evident that
early identiﬁcation of the condition is critical, as NAFLD, and in
particular its more severe form non-alcoholic steatohepatitis
(NASH), is linked strongly with the metabolic syndrome [1] and
has been identiﬁed as an independent factor for cardiovascular
disease [2]. Furthermore there are accumulating data in relation
to the progression of NASH to cirrhosis, with estimates that
almost 1 in 10 liver transplants will be performed for NASH cir-
rhosis in the coming decades [3], as well as to the development
of hepatocellular carcinoma [4]. It is therefore a major public
health issue. At present, a liver biopsy is the gold standard for
the diagnosis and classiﬁcation of NAFLD [5] with histological
assessment carried out according to various classiﬁcations [6–
8]. A liver biopsy has the advantage of providing important infor-
mation relating to the degree of liver damage, changes in the
overall liver architecture, as well as the severity of inﬂammatory
activity and ﬁbrosis. However, it is an invasive test, has inherent
complications, is expensive, and is operator/analyser dependent.
As a result there have been ongoing efforts to identify a reliable
non-invasive means of assessing the presence and severity of
NAFLD in at-risk populations.
In this issue of Journal of Hepatology, Li et al. [9] report the
results of a study examining the potential role of ﬁbroblast
growth factor 21 (FGF21) as a biomarker for identifying the pres-
ence of NAFLD. The rationale for their study was that FGF21 had
been shown to be an important regulator of hepatic glucose and
lipid metabolism in animal models [10] and its levels tend to be
elevated in obese subjects and correlated with markers of insulin
resistance [11]. While the investigators’ previous work had dem-
onstrated that FGF21 concentrations correlated with gamma
glutaryl transferase (GGT) and aspartate aminotransferase (AST)
levels in Chinese subjects [12], the current study population con-
sisted of 224 adult Chinese patients with a diagnosis of NAFLD
based on B-mode ultrasonography and 124 controls with a nor-Journal of Hepatology 20
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were performed in all patients and blood samples were obtained
for the determination of FGF21, ALT, and GGT, as well as markers
of lipid and glucose metabolism. The FGF21 concentrations were
determined by a commercially available ELISA. In addition, the
group classiﬁed the degree of hepatic steatosis and measured
both FGF21 and lipid concentrations in liver samples from 17
patients undergoing resection for benign liver lesions. Li and col-
leagues demonstrated that serum FGF21 levels were signiﬁcantly
higher in the NAFLD group compared to the controls, and higher
in NASH patients compared to those with fatty liver. The FGF21
levels associated positively with most indices under investigation
while for high density lipoprotein cholesterol there was a signif-
icant negative association. Twelve of 17 liver biopsies exhibited
hepatic steatosis with FGF21 mRNA expression increasing with
the degree of steatosis and with the degree of FGF21 protein
expression within the liver; both plasma and hepatic FGF21 cor-
related with hepatic triglyceride concentrations. The authors con-
cluded that their results support the role of FGF21 as an
important regulator of hepatic lipid biochemistry and suggest
that FGF21 could act as a biomarker for NAFLD.
This study, along with the recent study by Dushay et al. [15],
represent an important contribution to the literature as they are
the ﬁrst to assess plasma FGF21 levels in patients with NAFLD.
With the current need for reliable biomarkers to screen and mon-
itor patients with NAFLD, this study [9] would suggest that FGF21
could potentially fulﬁl this role. There are however several limi-
tations to the current study which need to be addressed in future
investigations before plasma FGF21 can be adopted as a bio-
marker. The most important issue is the need to correlate
FGF21 with liver histology, the current gold standard for the diag-
nosis of NAFLD, and distinguish fatty liver from NASH. The
method of classiﬁcation utilised in this study, namely B-mode
ultrasound, has important limitations as a means of diagnosing
and determining disease severity [13]. This may explain the large
overlap in FGF21 levels between the groups as illustrated in Fig. 1
since a number of the controls, in particular those with impaired
glucose tolerance may have had sub-radiological hepatic steato-
sis. This overlap would certainly preclude FGF21 being used as
a biomarker to screen patients. A second shortcoming is the use
of liver biopsies from patients undergoing resection for benign10 vol. 53 j 795–796
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liver disease. There are several issues related to choosing this tis-
sue for the analysis of FGF21 mRNA. The mechanism for the
development of steatosis is complex and varied between differ-
ent disease states and may not be the same in these cases of ‘inci-
dental’ steatosis as for NAFLD. Another area of concern is the use
of transaminase levels to classify patients with ultrasound-
detected steatosis as fatty liver or NASH as this can only be deter-
mined by a liver biopsy and it has been well established that
serum ALT is a poor predictor of NASH with the full spectrum
of disease severity found in patients with normal transaminases
[14].
With NAFLD now being recognised as a major public health
problem, there is certainly the need for reliable biomarkers to
identify and monitor those at risk of disease progression and
potentially spare them from an invasive liver biopsy. The work
presented by Li and co-workers in this edition of the Journal of
Hepatology suggests that FGF21 may potentially fulﬁl this role,
as corroborated by the study by Dushay et al. that was published
when this article went to press [15]. However at present, further
studies are required to clarify some muddy waters and validate
the results reported herein.
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